Literature DB >> 22975837

Ambivalence among neurologists and neurosurgeons on the treatment of chronic subdural hematoma: a national survey.

L M E Berghauser Pont1, D W J Dippel, B H Verweij, C M F Dirven, R Dammers.   

Abstract

No class I evidence exists about the optimal treatment of chronic subdural hematoma (CSDH). The aim of this study was to evaluate current practice of CSDH patients with different neurological grades, and probable ambivalence towards various treatment paradigms, especially primary treatment with high-dose corticosteroids, among vascular neurologists and neurosurgeons. A questionnaire survey containing 4 questions, 1 consisting of cases, was sent to every vascular neurologist (n = 83) and neurosurgical centre (n = 15) in the Netherlands. The various treatment options were related to the treating physician, geographical distribution, both in general and for individual case. Sixty-two percent of surveys were returned. The proportion of patients primarily treated with corticosteroids was 17.5 % in 2009 and 20.5 % in 2010. Surgery by either burr holes or craniotomy was favoured by 61.1 % as primary treatment, and conservative treatment with corticosteroids by 22.4 %. Case studies revealed that surgery was preferred in case of severe neurological symptoms, whereas wait-and-see policy was preferred in case of mild symptoms without midline shift, of which 28 % would administer corticosteroids. Variety in answers was obtained in less pronounced cases. In the Netherlands, neurologists and neurosurgeons appear to favour surgery in CSDH patients as primary treatment, especially in severe cases. An ambivalent approach towards treatment protocols was shown, especially in patients with mild symptoms, regardless of hematoma size. A regimen of high-dose corticosteroids only, is preferred by about a quarter and predominantly in milder cases, and might depend on geographical distribution. These results suggest the need for a well-designed randomized trial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975837     DOI: 10.1007/s13760-012-0130-1

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  6 in total

1.  Benefits of the Subdural Evacuating Port System (SEPS) Procedure Over Traditional Craniotomy for Subdural Hematoma Evacuation.

Authors:  Danielle Golub; Kimberly Ashayeri; Siddhant Dogra; Ariane Lewis; Donato Pacione
Journal:  Neurohospitalist       Date:  2020-05-04

Review 2.  The pathophysiology of chronic subdural hematoma revisited: emphasis on aging processes as key factor.

Authors:  Ralf Weigel; Lothar Schilling; Joachim K Krauss
Journal:  Geroscience       Date:  2022-04-23       Impact factor: 7.581

3.  The efficacy of dexamethasone on reduction in the reoperation rate of chronic subdural hematoma--the DRESH study: straightforward study protocol for a randomized controlled trial.

Authors:  Stephan Emich; Bernd Richling; Marc R McCoy; Rahman Abdul Al-Schameri; Feng Ling; Liyong Sun; Yabing Wang; Wolfgang Hitzl
Journal:  Trials       Date:  2014-01-06       Impact factor: 2.279

Review 4.  Chronic subdural haematoma: modern management and emerging therapies.

Authors:  Angelos G Kolias; Aswin Chari; Thomas Santarius; Peter J Hutchinson
Journal:  Nat Rev Neurol       Date:  2014-09-16       Impact factor: 42.937

Review 5.  The Role of Medical Treatment in Chronic Subdural Hematoma.

Authors:  Amit Kumar Thotakura; Nageswara Rao Marabathina
Journal:  Asian J Neurosurg       Date:  2018 Oct-Dec

6.  Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial.

Authors:  S Immenga; R Lodewijkx; Y B W E M Roos; S Middeldorp; C B L M Majoie; H C Willems; W P Vandertop; D Verbaan
Journal:  Trials       Date:  2022-01-18       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.